托法替布治疗银屑病关节炎患者的疗效、安全性和持续性的性别差异:3期试验和长期扩展的事后分析
该事后分析汇总了两项3期随机对照试验,评估托法替布在银屑病关节炎患者中疗效、安全性和持续性的性别差异。结果显示托法替布疗效在男女两性中均优于安慰剂且两性间总体相当,但女性达到MDA的可能性较低,安全性和停药时间两性总体相似。
要点
- 托法替布疗效在男女两性中均超过安慰剂,且两性间总体相当。
- 女性达到MDA的可能性低于男性,可能与基线差异有关。
- 托法替布安全性和停药时间在男女两性间总体相似。
核心结论
- 托法替布疗效在男女两性中均超过安慰剂且两性间相当,女性达到MDA的可能性较低,安全性和停药时间两性总体相似。
研究设计与样本
- 事后分析汇总两项3期随机对照试验,纳入816例银屑病关节炎患者,女性占54.3%,随机接受托法替布5 mg或10 mg每日两次、阿达木单抗40 mg每2周或安慰剂。
主要发现
- 基线时女性报告更高的压痛关节计数、附着点炎评分及更差的HAQ-DI和FACIT-F,男性附着指炎和PASI更高。
- 第3个月时托法替布疗效在男女两性中均普遍超过安慰剂。
- 托法替布在男女两性间观察到相似的ACR20/50/70、PASI75、ΔHAQ-DI和ΔFACIT-F,但女性达到MDA的可能性较低。
- 接受托法替布(两种剂量)的男女两性发生治疗中出现的不良事件比例相似。
- 托法替布5 mg每日两次组严重不良事件男性3.4%、女性6.6%,10 mg每日两次组男性4.0%、女性5.9%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evaluate the impact of sex on tofacitinib efficacy, safety and persistence (time to discontinuation) in patients with psoriatic arthritis (PsA). METHODS: Data were pooled from two phase 3 randomised controlled trials. Patients were randomised to tofacitinib 5 mg or 10 mg two times per day, adalimumab 40 mg every 2 weeks or placebo. Efficacy outcomes to month 12 included American College of Rheumatology (ACR)20/50/70, minimal disease activity (MDA), Psoriasis Area Severity Index (PASI)75, change from baseline (∆) in Health Assessment Questionnaire-Disability Index (HAQ-DI) and ∆Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). Safety was assessed to month 12 and persistence was assessed to month 42 of a long-term extension study. RESULTS: Overall, 816 patients were included (54.3% females). At baseline, higher tender joint counts, enthesitis scores and worse HAQ-DI and FACIT-F were reported in females versus males; presence of dactylitis and PASI were greater in males versus females. At month 3, tofacitinib efficacy generally exceeded placebo in both sexes. Overall, similar ACR20/50/70, PASI75, ∆HAQ-DI and ∆FACIT-F were observed for tofacitinib between sexes; females were less likely to achieve MDA. Similar proportions of males/females receiving tofacitinib (both doses) experienced treatment-emergent adverse events (AEs). Serious AEs occurred in 3.4%/6.6% and 4.0%/5.9% males/females with tofacitinib 5 mg and 10 mg two times per day. Persistence was generally similar between sexes. CONCLUSION: Tofacitinib efficacy exceeded placebo in both sexes and was comparable between sexes. Consistent with previous studies of PsA treatments, females were less likely to achieve MDA, likely due to baseline differences. Safety and time to discontinuation were generally similar between sexes. TRIAL REGISTRATION NUMBER: NCT01877668; NCT01882439; NCT01976364.
引用
- Eder L, Gladman DD, Mease P, et al. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023. PMID: 36958766. doi:10.1136/rmdopen-2022-002718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。